Is more than one quinolone needed in clinical practice?

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1085-1095

  Paladino, J A ^a  

^a CPL Associates LLC   (United States)

Author keywords

Fluoroquinolones; Infectious diseases

Indexed keywords

ANTACID AGENT; ENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SPARFLOXACIN; THEOPHYLLINE DERIVATIVE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL PRACTICE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; HYPERSENSITIVITY; INFECTION; LIVER FAILURE; LIVER TOXICITY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; SEIZURE; TREATMENT PLANNING;

EID: 0034836291     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002800103500906     Document Type: Article

References (129)

1. Mechanisms of action of and resistance to quinolone antimicrobial agents
2. Chemistry mode of action
3. DNA gyrase, topoisomerase IV, and the 4-quinolones
4. Trends in bacterial resistance to fluoroquinolones
5. Bacterial multidrug resistance - Emphasis on efflux mechanisms and Pseudomonas aeruginosa
6. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae
7. Fluoroquinolone antimicrobial agents
8. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin
9. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin
10. Current activity of ciprofloxacin against gram-negative bacilli in the United States
11. Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997 to 1998
12. Prevalence of resistance to three fluoroquinolones: Assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility
13. Ciprofloxacin, ofloxacin, and levofloxacin activity against multiply-resistant Pseudomonas aeruginosa
14. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility
15. Fluoroquinolones
16. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects
17. Quinolone pharmacokinetics
18. Pharmacokinetics and tissue penetration of quinolones
19. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro
20. Interactions between oral ciprofloxacin and caffeine in normal volunteers
21. Quinolones: A practical review of clinical uses, dosing considerations, and drug interactions
22. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects
23. Pharmacokinetic drug interactions with oral contraceptives
24. Oral contraceptives. Are drug interactions of clinical significance?
25. Ciprofloxacin absorption is impaired in patients given enternal feedings orally and via gastrostomy and jejunostomy tubes
26. Decreased in vitro fluoroquinolone concentrations after admixture with an enternal feeding formulation
27. Levofloxacin and trovafloxacin: The next generation of fluoroquinolones?
28. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
29. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens
30. Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria
31. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis
32. In vitro activity of ofloxacin against Mycobacterium tuberculosis
33. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance
34. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar
35. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
36. Increasing prevalence of antimicrobial resistance among uropathogens causing uncomplicated cystitis in women
37. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection
38. The fluoroquinolones for urinary tract infections: A review
39. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults
40. A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections
41. Clinical experience with ofloxacin in upper and lower urinary tract infections: A comparison with cotrimoxazole and nitrofurantoin
42. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection
43. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women: The minimum effective dose
44. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women
45. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin
46. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women
47. Efficacy of single-dose therapy with levofloxacin for acute cystitis: Comparison to three-day therapy
48. Oral bioequivalence and efficacy of ciprofloxacin (CIP) suspension (Susp) for treatment of acute urinary tract infection (UTI)
49. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women
50. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis
51. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection
52. Ofloxacin compared to ciprofloxacin in the treatment of complicated lower urinary tract infections
53. Open randomized comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections
54. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections
55. Comparative clinical study of ciprofloxacin and norfloxacin in the treatment of complicated urinary tract infections
56. Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection
57. The changing bacterial etiology of chronic obstructive pulmonary disease (COPD)
58. Levofloxacin: A review of its antibacterial activity, pharmacokinetic and therapeutic efficacy
59. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability
60. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis
61. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomized, parallel, multicentre study
62. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study
63. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis
64. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
65. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
66. The efficacy and safety of a new ciprofloxacin suspension compared with coamoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis
67. The role of fluoroquinolones in respiratory tract infections
68. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian Ciprofloxacin Health Economic Study Group
69. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
70. Comparative study of levofloxacin (LVFX) and co-amoxiclav (Co-AC) in the treatment of community-acquired pneumonia (CAP) in adults
71. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
72. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
73. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
74. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study
75. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
76. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia
77. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
78. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization
79. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia
80. Treating community-acquired pneumonia with once-daily gatifloxacin vs. once-daily levofloxacin
81. Nosocomial bronchopneumonia in the critically ill: Histologic and bacteriologic aspects
82. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections
83. Treatment of severe pneumonia in hospitalized patients: Results of a multicentre, randomized double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
84. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
85. Studies on the synergism of ciprofloxacin with β-lactam antibiotics, gentamicin, minocycline and pipemidic acid
86. Comprehensive evaluation of ciprofloxacin in combination with β-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa
87. Lomefloxacin vs ciprofloxacin in the treatment of non-necrotising skin and skin structure infections
88. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections
89. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections
90. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections
91. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure
92. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin and DU-6869a) in the treatment of anaerobic infections: Review of current information on efficacy and safety
93. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates
94. Oral ciprofloxacin vs. parenteral cefotaxime in the treatment of difficult skin and skin structure infections: A multicenter trial
95. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections
96. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections
97. Antimicrobial therapy for chronic osteomyelitis in adults: Role of the quinolones
98. Treatment of posttraumatic osteitis with intravenous ofloxacin
99. Use of ofloxacin in open fractures and in the treatment of post-traumatic osteomyelitis
100. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis
101. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis
102. Ofloxacin versus parenteral therapy for chronic osteomyelitis
103. The safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of acute and chronic osteomyelitis
104. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis
105. Evaluation of new anti-infective drugs for the treatment of intra-abdominal infections
106. Results of a randomized trial comparing sequential IV/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections
107. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections
108. Trovafloxacin in the treatment of intra-abdominal infections: Results of a double-blind, multicenter comparison with imipenem/cilastatin
109. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients
110. NCCN practice guidelines for fever and neutropenia
111. Ciprofloxacin/piperacillin vs tobramycin/piperacillin as empiric therapy for fever in neutropenic cancer patients
112. Quinolone antibacterials: An update of their pharmacology and therapeutic use
113. Ofloxacin-induced seizure
114. Risk of seizures from concomitant use of ciprofloxacin and phenytoin in patients with epilepsy
115. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin
116. Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea-like), visual hallucination in two elderly patients
117. Trovafloxacin
118. FDA/RhRMA task force to assess QT risk by preclinical markers
119. Gatifloxacin-induced QTc prolongation and ventricular tachycardia
120. Seven Achilles tendonitis including 3 complicated by rupture during fluoroquinolone therapy
121. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy
122. Economic impact of oral ciprofloxacin following standard intravenous therapy
123. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics
124. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics